To even the most optimistic soul, 2022 was not a vintage year for the world of biopharma and medtech. Public markets continued their downward trajectory and many investors sought safe havens far away from the riskier biotech companies. Little more than a handful of IPOs took place and those that did were small and mostly unremarkable.
The geopolitical and economic landscape at the start of 2023 are hardly reasons to be turning cartwheels, but there are signs that M&A might be picking up and there are some interesting catalysts pending in the coming months. Is the worst behind us?
For this eBook, the Evaluate Vantage team braced themselves to investigate the good, the bad and the ugly of the past 12 months.
Download Now
Share
Related Blogs
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the ...
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...